For 120 adults seeking obesity treatment, a 60-week study at the University of Pennsylvania found that semaglutide was linked not only to greater weight loss, but also to improvements in several measures of eating behavior and body image.
The findings matter because weight treatment can involve more than changes on a scale. Some people also struggle with binge eating, feeling unable to control their eating, or distress about their weight and body shape. Researchers have been interested in how GLP-1 medicines—a class of drugs used for obesity treatment—may affect these concerns. The Penn study, led by researchers at the Perelman School of Medicine, was published in the International Journal of Eating Disorders.
Participants were randomly assigned to receive either 2.4 milligrams of semaglutide or a placebo, a treatment with no active drug. Both groups also took part in a structured lifestyle program that included food counseling and guidance on physical activity. After 60 weeks, the semaglutide group had lost about 15% of their body weight on average. The placebo group lost about 3%.
The researchers also found larger improvements among participants receiving semaglutide in loss-of-control eating, overall eating disorder symptoms, and concerns about weight and shape. People in this group reported greater improvement in body dissatisfaction and body image than those receiving placebo.
For participants who began the study with binge-eating episodes or full or less severe forms of binge-eating disorder, semaglutide was also linked to a greater chance of remission and stopping binge-eating behaviors. New eating disorder symptoms and major worsening of eating-related problems were uncommon in both groups. The study’s results therefore point toward improvement on average, rather than a broad increase in eating-related problems.
Kelly Costello Allison, director of Penn’s Center for Weight and Eating Disorders and the study’s first author, said the findings suggest semaglutide may support weight loss while also improving some measures of eating disorder symptoms and loss-of-control eating. Senior author Jena Tronieri, a research investigator at the same center, said the results were encouraging, especially for people dealing with both obesity and binge eating.
The researchers also urged care in interpreting the results. A small number of participants experienced disordered eating behaviors during the study, and the team said people with a history of eating disorders should be monitored during treatment. The study involved 120 adults, so larger studies are needed, particularly among people diagnosed with binge-eating disorder or with a history of other eating disorders.
For now, the findings offer a reason to study these effects more closely, not a guarantee that every patient will respond in the same way. Allison said eating behaviors should be assessed regularly during treatment so that people who develop concerning symptoms can receive appropriate care. The next step is to test the results in larger groups and learn more about who may benefit—and who may need extra support.
